Valeant Pharmaceuticals International (VRX) Price Target Raised to $10.00

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) had its price target boosted by Mizuho from $7.00 to $10.00 in a research note released on Friday, MarketBeat.com reports. Mizuho currently has an underperform rating on the specialty pharmaceutical company’s stock.

Several other research firms have also commented on VRX. Zacks Investment Research lowered shares of Valeant Pharmaceuticals International from a hold rating to a sell rating in a research report on Thursday, October 12th. Piper Jaffray Companies set a $14.00 price target on shares of Valeant Pharmaceuticals International and gave the company a sell rating in a research report on Sunday, October 22nd. Vetr upgraded shares of Valeant Pharmaceuticals International from a strong sell rating to a sell rating and set a $12.46 price target on the stock in a research report on Monday, September 18th. Wells Fargo & Company reaffirmed a sell rating on shares of Valeant Pharmaceuticals International in a report on Monday, November 13th. Finally, HC Wainwright reaffirmed a hold rating and set a $17.00 price objective on shares of Valeant Pharmaceuticals International in a report on Monday, September 18th. Six investment analysts have rated the stock with a sell rating, ten have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Hold and a consensus target price of $17.72.

Shares of Valeant Pharmaceuticals International (NYSE:VRX) opened at $21.20 on Friday. The company has a market cap of $6,870.75, a price-to-earnings ratio of 3.20, a P/E/G ratio of 0.54 and a beta of -0.22. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 4.84. Valeant Pharmaceuticals International has a 52-week low of $8.31 and a 52-week high of $22.81.

In other Valeant Pharmaceuticals International news, Director John Paulson purchased 344,216 shares of the firm’s stock in a transaction dated Thursday, November 16th. The shares were purchased at an average cost of $14.40 per share, with a total value of $4,956,710.40. Following the completion of the purchase, the director now owns 94,559 shares in the company, valued at approximately $1,361,649.60. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 5.87% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Paulson & CO. Inc. lifted its stake in shares of Valeant Pharmaceuticals International by 12.5% in the second quarter. Paulson & CO. Inc. now owns 21,813,400 shares of the specialty pharmaceutical company’s stock worth $377,372,000 after buying an additional 2,428,900 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Valeant Pharmaceuticals International by 4.2% in the second quarter. Vanguard Group Inc. now owns 7,274,717 shares of the specialty pharmaceutical company’s stock worth $125,853,000 after buying an additional 294,643 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Valeant Pharmaceuticals International by 327.6% in the third quarter. Dimensional Fund Advisors LP now owns 4,472,185 shares of the specialty pharmaceutical company’s stock worth $64,086,000 after buying an additional 3,426,410 shares in the last quarter. CIBC World Markets Inc. lifted its stake in shares of Valeant Pharmaceuticals International by 2.3% in the second quarter. CIBC World Markets Inc. now owns 3,741,413 shares of the specialty pharmaceutical company’s stock worth $64,726,000 after buying an additional 83,592 shares in the last quarter. Finally, Chou Associates Management Inc. lifted its stake in shares of Valeant Pharmaceuticals International by 29.7% in the second quarter. Chou Associates Management Inc. now owns 3,053,843 shares of the specialty pharmaceutical company’s stock worth $53,030,000 after buying an additional 700,000 shares in the last quarter. 49.49% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://sportsperspectives.com/2017/12/19/valeant-pharmaceuticals-international-vrx-price-target-raised-to-10-00.html.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply